AB-Amy

Antibody

Antibodies play an indispensable role in the vertebrate immune defence system. They also serve as essential agents in biomedical research and clinical diagnostic assays such as enzyme-linked immunosorbent assay, immunohistochemical assay, and immunoprecipitation assay. Furthermore, antibodies have been extensively used in clinical treatment of many types of cancers, autoimmune diseases, and infectious diseases including the coronavirus disease 2019, which is caused by the severe acute respiratory syndrome coronavirus 2.

Light-Chain(AL) Amyloid

AL amyloidosis, known as primary amyloidosis,is coursed by abnormal clone plasma cells overproducing monoclonal immunoglobulin light chains that misfold, aggregate as amyloid fibrils in target organs. The abnormal antibodies are deposited in tissues as amyloid proteins, interfering with normal physiological functions, thereby causing amyloidosis. AL amyloidosis is a multiorgan disease. It most commonly affects the kidney, vasculature, liver,gastrointestinal tract and nervous system

What is AB-Amy？

AB-Amy is the first tool for predicting AL amyloidosis in therapeutic antibodies, which enables rapid screening of antibody drug candidates with the risk of amyloidosis in early development stages, thereby saving cost and time in drug development.

In this study, we collected 742 amyloidogenic and 712 non-amyloidogenic VL sequences to build a support vector machine -based model, named AB-Amy, for predicting the amyloidosis tendency of therapeutic antibodies. AB-Amy achieved the sensitivity, specificity, MCC, ACC and AUC of 93.80%, 91.98%, 92.95%, 0.8584 and 0.9651, respectively.

Citation:Yuwei Zhou and others, AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains, Antibody Therapeutics, 2023;, tbad007, https://doi.org/10.1093/abt/tbad007